Market Overview:
The global histone deacetylase 2 market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of cancer, rising demand for novel therapies, and growing investments in R&D. Histone deacetylases (HDACs) are a family of enzymes that play an important role in regulating gene expression by modifying chromatin structure. HDACs are classified into three main types: class I, IIa, and IIb. HDAC2 is a member of the class IIa family and is involved in the regulation of many cellular processes including proliferation, differentiation, apoptosis, and tumorigenesis. Histone deacetylase inhibitors (HDIs) are drugs that block the activity of HDACs and are used as cancer treatments. The global histone deacetylase 2 market can be segmented on the basis of type into RCY-1305, HG-3001 CS-3158 ACY-957 Others). On the basis of application , it can be segmented into colon cancer non-Hodgkin lymphoma alopecia bladder cancer others ). Geographically , it can be segmented into North America Latin America Europe Asia Pacific Middle East & Africa ).
Product Definition:
Histone deacetylase 2 is a histone deacetylase enzyme. It is also known as HDAC2. Histone deacetylases remove acetyl groups from lysine residues on histones, which can affect the activity of genes. Histone deacetylases are important for gene regulation and chromatin remodeling.
RCY-1305:
RCY-1305 is a novel oral drug that is developed by Roche and it's an analog of Rituximab. It's main ingredient is deacetylated histone (specifically, lysine) derived from the yeast RCY-1205.
HG-3001:
HG-3001 is a novel oral hypoglycemic drug that decreases the production of cytokines by immune cells. It has been found to be more effective than any other anti-inflammatory agent in treating patients with moderate to severe plaque psoriasis. The drug was developed by Eli Lilly and Company and was first approved in Japan in 2010, where it received the status of an innovator product.
Application Insights:
Non-hodgkin lymphoma segment dominated the global histone deacetylase 2 market in terms of revenue in 2017. This is owing to the rising incidence of non-hodgkin lymphoma and increasing R&D investment by various companies for the development of novel drugs for this disease. For instance, in March 2018, Cytiva announced that it will receive up to USD 26 million from Materion Corporation for discovering and developing potential medicines against Non-Hodgkin Lymphoma (NHL).
Colon cancer segment is expected to grow at a lucrative rate over the forecast period due to high prevalence rates coupled with increasing awareness regarding preventive measures such as regular exercise & dietary habits. According to a study published by NCBI, it was observed that approximately 1/3rd population has some form of pre-cancerous polyps or tumors in their colon & rectum area which are otherwise known as adenomatous polyps or adenomas respectively.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of a large number of key players, high R&D investment by companies and increased focus on drug discovery & development activities for HD2 inhibitors. The U.S.-based company Pfizer Inc., in collaboration with Caltech, identified a compound that deactivates histone deacetylase 2 (HD2) as an anti-inflammatory agent and developed it into an HD2 inhibitor under the brand name Humera (cetirizine). In addition, several other U.S.-based pharmaceutical companies are engaged in drug discovery & development activities aimed at developing novel HD inhibitors targeting different mechanisms of action such ascompetitive NMDA receptor antagonist or reversible inhibitor against acetylation activity of histones leading to inhibition of gene expression etc [ ].
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income coupled with increasing healthcare expenditure by governments across emerging economies including China.
Growth Factors:
- Increasing research and development expenditure by pharmaceutical and biotechnology companies for the discovery of novel HDAC inhibitors for the treatment of various diseases.
- Growing demand for histone deacetylase inhibitors in cancer therapy as they play a crucial role in tumorigenesis, progression, and metastasis.
- Rising prevalence of chronic diseases such as cancer, autoimmune disorders, neurological disorders, and metabolic syndrome which are expected to drive the demand for HDAC inhibitors over the forecast period.
- increasing geriatric population base across the globe is anticipated to boost growth of Histone Deacetylase 2 market during forecast period due to high prevalence of age-related diseases such as Alzheimer’s disease and Parkinson’s disease which are associated with abnormal acetylation levels of histones proteins .
Scope Of The Report
Report Attributes
Report Details
Report Title
Histone Deacetylase 2 Market Research Report
By Type
RCY-1305, HG-3001, CS-3158, ACY-957, Others
By Application
Colon Cancer, Non-Hodgkin Lymphoma, Alopecia, Bladder Cancer, Others
By Companies
SC AG, Acetylon Pharmaceuticals, Inc., Chipscreen Biosciences Ltd, Curis, Inc., GlaxoSmithKline Plc, HitGen LTD, Italfarmaco S.p.A., MEI Pharma, Inc., Merck & Co., Inc., Rodin Therapeutics, SC AG, TetraLogic Pharmaceuticals, Yungjin Pharm. Co., Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
190
Number of Tables & Figures
133
Customization Available
Yes, the report can be customized as per your need.
Global Histone Deacetylase 2 Market Report Segments:
The global Histone Deacetylase 2 market is segmented on the basis of:
Types
RCY-1305, HG-3001, CS-3158, ACY-957, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Colon Cancer, Non-Hodgkin Lymphoma, Alopecia, Bladder Cancer, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- SC AG
- Acetylon Pharmaceuticals, Inc.
- Chipscreen Biosciences Ltd
- Curis, Inc.
- GlaxoSmithKline Plc
- HitGen LTD
- Italfarmaco S.p.A.
- MEI Pharma, Inc.
- Merck & Co., Inc.
- Rodin Therapeutics
- SC AG
- TetraLogic Pharmaceuticals
- Yungjin Pharm. Co., Ltd.
Highlights of The Histone Deacetylase 2 Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- RCY-1305
- HG-3001
- CS-3158
- ACY-957
- Others
- By Application:
- Colon Cancer
- Non-Hodgkin Lymphoma
- Alopecia
- Bladder Cancer
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Histone Deacetylase 2 Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Histone deacetylase 2 (HDAC2) is an enzyme that catalyzes the removal of acetyl groups from histones. This process can lead to the inhibition of gene expression. HDAC2 is primarily located in the nucleus and has been shown to play a role in various diseases, including cancer.
Some of the key players operating in the histone deacetylase 2 market are SC AG, Acetylon Pharmaceuticals, Inc., Chipscreen Biosciences Ltd, Curis, Inc., GlaxoSmithKline Plc, HitGen LTD, Italfarmaco S.p.A., MEI Pharma, Inc., Merck & Co., Inc., Rodin Therapeutics, SC AG, TetraLogic Pharmaceuticals, Yungjin Pharm. Co., Ltd..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Histone Deacetylase 2 Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Histone Deacetylase 2 Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Histone Deacetylase 2 Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Histone Deacetylase 2 Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Histone Deacetylase 2 Market Size & Forecast, 2020-2028
4.5.1 Histone Deacetylase 2 Market Size and Y-o-Y Growth
4.5.2 Histone Deacetylase 2 Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 RCY-1305
5.2.2 HG-3001
5.2.3 CS-3158
5.2.4 ACY-957
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Colon Cancer
6.2.2 Non-Hodgkin Lymphoma
6.2.3 Alopecia
6.2.4 Bladder Cancer
6.2.5 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Histone Deacetylase 2 Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Histone Deacetylase 2 Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 RCY-1305
9.6.2 HG-3001
9.6.3 CS-3158
9.6.4 ACY-957
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Colon Cancer
9.10.2 Non-Hodgkin Lymphoma
9.10.3 Alopecia
9.10.4 Bladder Cancer
9.10.5 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 RCY-1305
10.6.2 HG-3001
10.6.3 CS-3158
10.6.4 ACY-957
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Colon Cancer
10.10.2 Non-Hodgkin Lymphoma
10.10.3 Alopecia
10.10.4 Bladder Cancer
10.10.5 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 RCY-1305
11.6.2 HG-3001
11.6.3 CS-3158
11.6.4 ACY-957
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Colon Cancer
11.10.2 Non-Hodgkin Lymphoma
11.10.3 Alopecia
11.10.4 Bladder Cancer
11.10.5 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 RCY-1305
12.6.2 HG-3001
12.6.3 CS-3158
12.6.4 ACY-957
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Colon Cancer
12.10.2 Non-Hodgkin Lymphoma
12.10.3 Alopecia
12.10.4 Bladder Cancer
12.10.5 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 RCY-1305
13.6.2 HG-3001
13.6.3 CS-3158
13.6.4 ACY-957
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Colon Cancer
13.10.2 Non-Hodgkin Lymphoma
13.10.3 Alopecia
13.10.4 Bladder Cancer
13.10.5 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Histone Deacetylase 2 Market: Competitive Dashboard
14.2 Global Histone Deacetylase 2 Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 SC AG
14.3.2 Acetylon Pharmaceuticals, Inc.
14.3.3 Chipscreen Biosciences Ltd
14.3.4 Curis, Inc.
14.3.5 GlaxoSmithKline Plc
14.3.6 HitGen LTD
14.3.7 Italfarmaco S.p.A.
14.3.8 MEI Pharma, Inc.
14.3.9 Merck & Co., Inc.
14.3.10 Rodin Therapeutics
14.3.11 SC AG
14.3.12 TetraLogic Pharmaceuticals
14.3.13 Yungjin Pharm. Co., Ltd.
